Compare Regeneron Pharmaceuticals Inc (REGN) vs iShares Silver Trust (SLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs iShares Silver Trust — how do they compare? Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.40B), while iShares Silver Trust trades at $54.49 (market cap $29.02B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2.6× iShares Silver Trust's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while iShares Silver Trust pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and iShares Silver Trust for 89 Days on average.
| REGN | SLV | |
|---|---|---|
Market Cap | $76.40B | $29.02B |
Volume | 626,381 | 16,510,334 |
Sector | Health | — |
52-Week High | $852.03 | $105.57 |
52-Week Low | $557.73 | $42.40 |
Typical Hold Time | 107 Days | 89 Days |
Enterprise Value | $71.12B | — |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
SLV (iShares Silver Trust) is trading at $53.82, down 2.94% with a bearish technical outlook. The ETF shows minimal operational activity with $0 revenue but generated $2.17M net income in 2024. Technical indicators show strong bearish momentum with 13 sell signals from moving averages, though RSI suggests potential oversold conditions. Recent news highlights silver's volatility amid Fed policy uncertainty and Treasury yield fluctuations.
Outlook remains cautious as silver faces pressure from rising rates and dollar strength. The ETF's structure provides pure silver exposure but carries metal price volatility risks. Near-term direction depends on Fed policy clarity and industrial demand trends, with technical support at $53-54 levels offering potential entry points for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →
